At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 66 enrolled
Drug / intervention
moxifloxacin 0.5% HCI ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
In Brief
A Phase 4 clinical trial evaluating moxifloxacin 0.5% HCI ophthalmic solution and gatifloxacin ophthalmic solution 0.3% for Anti-biotic Resistance. Completed, enrolled 66 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnti-biotic Resistance
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedApr 2009
Primary CompletionSep 2009
Study CompletionOct 2009
TodayJul 2026
First PostedApr 3, 2009
Enrollment StartMar 1, 2009
Primary CompletionSep 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.2 years ago
Interventions
moxifloxacin 0.5% HCI ophthalmic solutiondrug
1 drop in study eye three times a day for 14 days
gatifloxacin ophthalmic solution 0.3%drug
1 drop in study eye four times a day for 14 days